Skip to content
Medical Health Aged Care

Australian PrEP supply constraints to begin easing

Health Equity Matters < 1 mins read

 

Supplies of the HIV prevention medicine, PrEP, will begin to return to normal, with the Therapeutic Goods Administration and the Pharmaceutical Benefits Scheme listing a new manufacturer, Laurus Labs to help overcome a shortage.

Supply constraints will start to ease imminently, and it is anticipated the shortage will be resolved by early November after being constrained for the last six weeks. 

 

 

James Gray, Principal Director, Australia Program at Health Equity Matters, the peak body for communities affected by HIV, said: "It is expected PrEP will soon return to normal availability. If you have enough supply to cover you for the next few weeks, we ask you to hold off on sourcing more PrEP through pharmacies unless you are travelling overseas or live in a remote community. We also ask people to purchase only one bottle of PrEP (that is, 30 pills) at a time until the resumption of full supply and, likewise, pharmacists to only dispense one bottle at a time."

 

ASHM CEO Alexis Apostolellis said: "Doctors providing PrEP scripts should ask patients to hold off filling scripts until late October unless they are travelling, live in remote areas or are in immediate need of medication."

 

Another option for individuals who need PrEP is to import the medication through websites such as PrEPaccessNow. Additionally, there are several ways to take PrEP safely, including on-demand and periodic use, which involve reduced medication consumption. Community members are urged to discuss these options with their GP and consult health promotion websites like Emen8 to learn more about alternative ways to take PrEP.

 

 

To arrange an interview, call Nick Lucchinelli 0422229032

More from this category

  • Medical Health Aged Care, Science
  • 24/06/2025
  • 08:05
WEHI

Barcodes uncover early blueprints of our cellular origins

A landmark study by WEHI scientists has shed new light on one of the most fundamental mysteries of biology: how cells divide and grow…

  • Contains:
  • General News, Medical Health Aged Care
  • 24/06/2025
  • 07:00
Monash University

Education status associated with reduced life expectancy and quality of life in Australia: new study

Australian males aged 25 years with a high level of education (completion of a bachelor’s degree or above) have 7.3 years greater life expectancy…

  • Contains:
  • Medical Health Aged Care
  • 24/06/2025
  • 06:00
Vertex

Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People with Cystic Fibrosis

–With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time – – The expanded listing includes an additional 271 mutations, many of them rare – Sydney, 24 June 2025 – Vertex Pharmaceuticals today announced that as of 1 July 2025, the funding of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be expanded on the Pharmaceutical Benefits Scheme (PBS) to include patients with cystic fibrosis aged 2years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive to elexacaftor/tezacaftor/ivacaftor potentiation…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.